A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared with Ertapenem in Complicated Urinary Tract Infections

Trial Profile

A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared with Ertapenem in Complicated Urinary Tract Infections

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs Eravacycline (Primary) ; Ertapenem; Levofloxacin
  • Indications Bacterial infections; Urinary tract infections
  • Focus Registrational; Therapeutic Use
  • Acronyms IGNITE3
  • Sponsors Tetraphase Pharmaceuticals
  • Most Recent Events

    • 02 Nov 2017 According to a Tetraphase Pharmaceuticals media release, company plans to submit sNDA for IV eravacycline in complicated urinary tract infectionsin second half of 2018.
    • 14 Oct 2017 This trial has been Completed in Latvia (End date: 2017-09-25).
    • 09 Oct 2017 This trial has been Completed in Bulgaria(End date: 2017-09-25).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top